IDEXX Laboratories Inc
NASDAQ:IDXX

Watchlist Manager
IDEXX Laboratories Inc Logo
IDEXX Laboratories Inc
NASDAQ:IDXX
Watchlist
Price: 417.32 USD -2.63%
Market Cap: 34.2B USD
Have any thoughts about
IDEXX Laboratories Inc?
Write Note

IDEXX Laboratories Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

IDEXX Laboratories Inc
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
IDEXX Laboratories Inc
NASDAQ:IDXX
Income from Continuing Operations
$866.2m
CAGR 3-Years
5%
CAGR 5-Years
15%
CAGR 10-Years
16%
Becton Dickinson and Co
NYSE:BDX
Income from Continuing Operations
$1.7B
CAGR 3-Years
2%
CAGR 5-Years
8%
CAGR 10-Years
4%
Boston Scientific Corp
NYSE:BSX
Income from Continuing Operations
$1.8B
CAGR 3-Years
16%
CAGR 5-Years
12%
CAGR 10-Years
20%
Stryker Corp
NYSE:SYK
Income from Continuing Operations
$3.6B
CAGR 3-Years
24%
CAGR 5-Years
14%
CAGR 10-Years
19%
Abbott Laboratories
NYSE:ABT
Income from Continuing Operations
$5.8B
CAGR 3-Years
-7%
CAGR 5-Years
12%
CAGR 10-Years
14%
Intuitive Surgical Inc
NASDAQ:ISRG
Income from Continuing Operations
$2.3B
CAGR 3-Years
10%
CAGR 5-Years
12%
CAGR 10-Years
18%
No Stocks Found

IDEXX Laboratories Inc
Glance View

Market Cap
34.3B USD
Industry
Health Care
Economic Moat
Narrow

IDEXX Laboratories Inc. is a leading global provider of veterinary diagnostic products and services, dedicated to enhancing the health and well-being of pets worldwide. Founded in 1983, the company has established itself as an innovator in the animal healthcare market, offering a comprehensive range of diagnostic tests, equipment, and software that empower veterinarians to make informed decisions. With a consistent focus on research and development, IDEXX has expanded its portfolio to include cutting-edge solutions such as digital imaging and telemedicine, addressing the growing needs of the pet care industry. Their strategic partnerships and robust distribution channels further bolster their presence in both developed and emerging markets. For investors, IDEXX represents a compelling opportunity within a steadily growing sector. The company's recurring revenue model, driven by its suite of diagnostic tests and subscriptions to software solutions, ensures stable cash flow and predictability in earnings. IDEXX has also demonstrated impressive financial performance, characterized by strong revenue growth, high profit margins, and a commitment to shareholder returns. By harnessing trends in pet ownership and increasing expenditures on pet healthcare, IDEXX positions itself as a reliable player in the marketplace. With its dedication to innovation, customer service, and global expansion, IDEXX Laboratories Inc. stands poised for sustained growth, making it an attractive consideration for long-term investors.

IDXX Intrinsic Value
255.66 USD
Overvaluation 39%
Intrinsic Value
Price

See Also

What is IDEXX Laboratories Inc's Income from Continuing Operations?
Income from Continuing Operations
866.2m USD

Based on the financial report for Sep 30, 2024, IDEXX Laboratories Inc's Income from Continuing Operations amounts to 866.2m USD.

What is IDEXX Laboratories Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
16%

Over the last year, the Income from Continuing Operations growth was 5%. The average annual Income from Continuing Operations growth rates for IDEXX Laboratories Inc have been 5% over the past three years , 15% over the past five years , and 16% over the past ten years .

Back to Top